Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which trade-off actually serves income investors better after both companies reported earnings?
Second-quarter earnings season shook loose some rare discounts on five high-yield dividend stocks that Wall Street analysts still rate as Buys, and income-focused investors may not get another shot at these prices.
Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert,…
Not every fat dividend yield is worth chasing into retirement, and the difference between a durable income stream and a yield trap often hides in details most investors skip past entirely.
Retirement means living off your portfolio, not waiting for it to grow, and right now five familiar dividend giants are trading at prices that Wall Street considers deeply undervalued.
AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms…
Getting kicked off the Dow Jones Industrial Average sounds like a death sentence for a stock, but a handful of booted dividend giants went on to reward patient shareholders with stunning gains…
Healthcare is quietly stealing the spotlight from mega cap tech in 2026, and two S&P 500 giants are trading at valuations that suggest the market has not caught on yet.
When a regular paycheck disappears in retirement, the stakes of every investment decision skyrocket. These five high-yield stocks earning 6% or more are winning over Boomers who refuse to let rising prices…
Johnson and Johnson has quietly become one of the best-performing mega-caps of the past year, but with a fresh pullback and a pipeline firing on multiple cylinders, the bigger question is whether…
Johnson and Johnson just raised guidance while absorbing nine-figure litigation charges, and the stock is still near levels that have historically rewarded patient buyers. Whether the talc courtroom drama is drowning out…
Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but the reasons behind each selloff tell very different stories about which one actually…
Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be. The real question…
Pfizer and Amgen both grew revenue last quarter at nearly the same pace, but the engines driving that growth point toward two very different futures in oncology. One company is collecting cash…
Abbott is down nearly 23% this year while Pfizer dangles a 7% yield, and both just beat Q1 estimates. One of these discounts is a genuine buying opportunity and the other is…
